Additional Information
Market: ASX
Sector: Pharmaceuticals & Biotechnology
EPIC: STI
Latest Price: A$0.00  (0,00%)
52-week High: A$0.00
52-week Low: A$0.00
Market Cap: A$0.72M
1 year chart
Deal STI Tax Free*
*subject to change and depends on individual circumstances.
1 day chart
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Stirling Products
www.stirlingproducts.net
Deal Stirling Products Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

Stirling Products (ASX:STI) is a manufacturer and marketer of proprietary and/or patented pharmaceutical products and natural health products for its own interests as well as on a contractual basis for third parties.  Strategically, Stirling Products is positioned to capitalise on the rapidly changing conditions within the global ...

Read more
Pdf

Stirling Products inks deal with Innovative Biotech to trial Immunoxel in Nigeria

November 18 2009, 8:40am Stirling Products inks deal with Innovative Biotech to trial Immunoxel in Nigeria

Australian healthcare company Stirling Products Limited (ASX:STI) has entered into an agreement with Innovative Biotech Ltd. of Keffi, Nigeria and Maryland, USA to register, trial, and market Dzherelo, the clinical version of ImmunoXel in Nigeria and other regions of Africa.

Nigeria with a population of 140 million, like most other African countries has major TB and HIV infection rates.

Under the deal, Stirling will support some of the costs of product registration, as well as the clinical trial of its immunomodulator in patients with tuberculosis, HIV, and TB/HIV co-infection.

Innovative Biotech will assist in arranging the clinical trial and, subject to the results of the trial, will launch marketing and distribution in Nigeria and other African countries.

Dzherelo (Immunoxel) is a botanical preparation approved and registered for use in several countries in Asia and Africa.

The preparation has been the subject of over a dozen successful clinical trials in TB and drug resistant TB over the last 15 years.

The results of past clinical trials, which were all very positive, have been published in peer-reviewed medical journals.

In extended clinical studies involving more than 1,200 patients, Dzherelo has been to have shown significant effects:

1. Shortening (drastically) the required treatment period to achieve clearance of Mycobacterium and
2. Reversing the adverse (hepatic) effects of conventional anti-TB drugs,
3. Improving clinical endpoints such as weight gain and
4. Lower incidence of opportunistic infections, and improved quality of life.

Dzherelo has also been tested in AIDS patients in Ukraine, with promising results on T-lymphocyte profiles, favorable cytokine production and decreased viral load.

Dzherelo which is a potent immunomodulator has also demonstrated benefit in trials of other viral infections such flu and hepatitis viruses.

The new study to be conducted in Nigeria is designed to confirm and extend the positive results on TB/HIV co-infection that were observed in past trials.

The Nigerian Dzherelo trial in TB and HIV will have an interim analysis scheduled for halfway through the trial, at which point the company and its partner Innovative will recommend continuation of the trial and immediate commencement of patient treatment, especially for humanitarian reasons.

Dr Simon Agwale, the President of Innovative Biotech, advised that it was the extensive published track record of Dzherelo/Immunoxel in the treatment of TB in the Ukraine that started the demand among Nigerian clinicians to bring the product into Nigeria for a trial.

“The weight of data indicating beneficial effects of Dzherelo/Immunoxel in the treatment of TB, HIV, and even seasonal flu demands that further trials be carried out,” Dr Agwale said.

Dr Agwale is a highly respected virologist/vaccinologist with extensive clinical and basic research experience.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.